BlueWillow’s Intranasal Bird Flu Vaccine: A New Era for Mucosal Immunity BlueWillow Biologics, a leading clinical-stage biotech company, has announced positive findings from a peer-reviewed Nature Communications study demonstrating the potential of its intranasal vaccine approach against bird flu. The news marks a significant milestone in the pursuit of needle-free, mucosal vaccines that can prime…